Ständer S, Schmidt E, Zillikens D, et al. - Researchers performed this retrospective cohort study to examine the clinical and immunological characteristics of patients with dipeptidyl peptidase-4 inhibitor (DPP4i)-associated bullous pemphigoid (BP) and to ascertain if there are intraclass differences between different DPP4i agents. The sample consisted of all consecutive patients diagnosed with BP throughout the years 2009–2019 in a tertiary referral center. Participants in the study were 273 BP patients (mean age at diagnosis 79.1 ± 9.9 years), of whom 24 (8.8%) were associated with DPP4i. Despite lower levels of typically pathogenic antibodies, DPP4i-associated BP is characterized by a more severe blistering and erosive presentation.